[Methylphenidate double-blind trial: indication and performing].
Hyperkinetic disorders or attention-deficit/hyperactivity disorders (ADHD) are among the psychiatric diagnoses most often encountered in children and adolescents. Symptoms include inattention, hyperactivity and impulsivity. Within the multi-modal treatment system, the therapy with psychostimulants (e. g. methylphenidate) proved to be an effective in patients with ADHD. A double-blind trial is indicated in cases of unclear efficacy of methylphenidate at initial application or if psychostimulants have regularly been applied for more than one year with an leave-out trial delivering unequivocal results. Further it is helpful in verifying potential undesirable side effects and improving patients' compliance.
Bliznakova
L
L
Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters am Zentralinstitut für Seelische Gesundheit, Mannheim, Germany. Lucia.Bliznakova@zi-mannheim.de
Gerstner
S
S
Schmidt
M H
MH
Becker
K
K
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000697:Central Nervous System Stimulants; D008774:Methylphenidate